Q-omics provides the consensus-scored NOTCH2 profile across patient tissues and cancer cell-line models. NOTCH2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NOTCH2 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, NOTCH2 protein abundance shows 25,138 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRP, and GBM as cancer lineages where NOTCH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOTCH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOTCH2 survival associations across molecular data types. NOTCH2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOTCH2 RNA expression–survival associations across cancer types. High NOTCH2 expression shows unfavorable associations in ACC, BLCA and MESO, but favorable associations in ESCA, UCS and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NOTCH2 RNA expression.
This table summarizes NOTCH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NOTCH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOTCH2 shows lower tumor expression in KICH, UCEC and COAD and higher tumor expression in KIRP, CHOL and KIRC. The KIRP box plot shows higher NOTCH2 RNA expression in tumor versus normal tissue (log2 FC = +1.151, t-test p = .001).
This table shows molecular features associated with NOTCH2 in patient tissues and cancer cell lines. In patient samples, NOTCH2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NOTCH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
